Friedreich's ataxia is a progressive, multisystem disorder causing neurological disability along with musculoskeletal, metabolic, and cardiac involvement.1 A consistent feature is markedly reduced cardiopulmonary fitness, which matters clinically because peak aerobic capacity correlates with functional limitations and might affect long-term health risks. To address impaired cardiopulmonary function, a phase-2, single-site, randomised, 2 × 2 factorial trial tested whether an individualised, remotely supervised, home exercise programme, the NAD+ precursor nicotinamide riboside, or a combination thereof could improve cardiopulmonary fitness over 12 weeks in children and adults with Friedreich's ataxia.
Wednesday, April 22, 2026
Targeting exercise, energy, or both in Friedreich's ataxia
Schulz J, Reetz K.,
Targeting exercise, energy, or both in Friedreich's ataxia, The Lancet Neurology, 25, 435-437, doi:10.1016/S1474-4422(26)00129-8
